Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: Streetwise Reports
$46.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

FDA Approves Two Glaxosmithkline Plc Melanoma Drugs-Reuters


Wednesday, 29 May 2013 03:53am EDT 

Reuters reported that U.S. health regulators approved a pair of GlaxoSmithKline Plc drugs to treat advanced melanoma the deadliest form of skin cancer in patients with specific genetic mutations. It also approved a diagnostic test to detect the mutations. The Food and Drug Administration said it approved the drugs, Tafinlar and Mekinist, to be used as single agents and not in combination after the medicines delayed tumor growth in separate clinical trials. 

Company Quote

1478.5
14.0 +0.96%
27 Nov 2014